Leading medical diagnostics/research company announced today the release of
a polyclonal antibody specific for the soluble APP beta product.
DEDHAM, Mass., April 26 /PRNewswire/ -- Signet Laboratories, Inc., a
leading medical diagnostics/research company specializing in the
development of monoclonal antibodies and diagnostic assays for cancer,
infectious disease, and neurodegenerative disease, today announced the
availability of a polyclonal antibody specific for sAPPbeta, a cleavage
product of amyloid precursor protein.
Alzheimer's disease (AD) presently affects over 4 million people, a
number that is expected to quadruple over the next 15 years. There is no
known cure and diagnosis can only be confirmed post mortem. AD is
characterized pathologically by the formation of extracellular amyloid
plaques in the brains of patients. These plaques are predominantly composed
of beta amyloid protein, which is derived from the proteolytic processing
of amyloid precursor protein.
"Quantitative analysis of the cleavage products generated during the
processing of amyloid precursor protein is critical to the understanding of
the pathogenesis of Alzheimer's disease," said Joe Bertelsen, Neuroscience
Product Manager, Signet Laboratories, Inc. "Signet's sAPPbeta specific
antibody, the first of its kind commercially available to AD researchers,
will serve as a powerful tool in the development of diagnostic and
therapeutic strategies for this devastating disease."
About Signet Laboratories, Inc.
Signet Laboratories, Inc. (Dedham, MA) is a leading medical
diagnostics/research company specializing in the development of monoclonal
antibodies and diagnostic assays for cancer, infectious disease, and
neurodegenerative disease. Signet was created in 1989 as a commercial
spinout of Johnson & Johnson's Cambridge Research Laboratories, Inc.
The Company was founded to continue the mission originally established
at CRL -- the early detection and recurrence monitoring of patients with
cancer and infectious disease. Signet has developed patented technology for
diagnosis and recurrence monitoring and for risk assessment of asymptomatic
patients in these areas. For more than a decade, the Company has
aggressively maintained licensing and development programs, which are
responsible for its broad patent and intellectual property estate.
Contact Information
Signet Company Contact Neuroscience Contact
Colleen Scott Joseph Bertelsen
Signet Laboratories, Inc. Signet Laboratories, Inc.
180 Rustcraft Road 180 Rustcraft Road
Dedham, MA 02026 Dedham, MA 02026
Phone: 781.915.1404 Phone: 781.915.1402
Fax: 781.461.2456 Fax: 781.461.2456
http://www.signetlabs.com
cscott@signetlabs.com
SOURCE Signet Laboratories, Inc.
 back to top
Related links:
http://www.signetlabs.com/
CONTACT:
Colleen Scott, +1-781-915-1404,
cscott@signetlabs.com; or Joseph Bertelsen, +1-781-915-1402, both
of Signet Laboratories, Inc.
|
